Get the Stockscreener App
12.03
0.33%
0.04
Amarin Corp Adr stock is traded at $12.03, with a volume of 44,833.
It is up +0.33% in the last 24 hours and down -16.40% over the past month.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
See More
Previous Close:
$11.99
Open:
$11.99
24h Volume:
44,833
Relative Volume:
0.72
Market Cap:
$254.11M
Revenue:
$217.21M
Net Income/Loss:
$-33.72M
P/E Ratio:
-7.4241
EPS:
-1.6204
Net Cash Flow:
$25.63M
1W Performance:
-2.59%
1M Performance:
-16.40%
6M Performance:
-18.61%
1Y Performance:
-36.92%
1-Day Range:
$11.95
$12.20
1-Week Range:
$11.83
$12.34
52-Week Range:
$11.83
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Name
Amarin Corp Adr
Sector
Industry
Phone
353 1 6699 020
Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
12.03 | 254.11M | 217.21M | -33.72M | 25.63M | -1.6204 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-26 | Resumed | JP Morgan | Underweight |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Oct-25-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| May-06-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-04-22 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-12-21 | Downgrade | Goldman | Neutral → Sell |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| May-05-20 | Initiated | Northland Capital | Outperform |
| Mar-31-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-31-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Mar-13-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-02-20 | Initiated | Cowen | Outperform |
| Feb-18-20 | Upgrade | Citigroup | Neutral → Buy |
| Jan-06-20 | Initiated | JP Morgan | Neutral |
| Dec-16-19 | Downgrade | Stifel | Buy → Hold |
| Nov-20-19 | Initiated | Oppenheimer | Underperform |
| Nov-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Nov-15-19 | Reiterated | SVB Leerink | Outperform |
| Oct-31-19 | Initiated | Aegis Capital | Buy |
| Oct-15-19 | Initiated | Goldman | Neutral |
| Aug-14-19 | Initiated | SVB Leerink | Outperform |
| Jul-09-19 | Reiterated | Jefferies | Buy |
| Jun-17-19 | Initiated | ROTH Capital | Buy |
| Mar-22-19 | Initiated | Stifel | Buy |
View All
Amarin Corp Adr Stock (AMRN) Latest News
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
Amarin Corporation plc (AMRN) Options Chain - Yahoo! Finance Canada
Amarin Corporation plc (AMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Amarin Stock Price Forecast. Should You Buy AMRN? - StockInvest.us
Amarin Corporation plc (AMRN) Options ChainYahoo Finance - Yahoo! Finance Canada
Amarin Corporation plc (AMRN) Options ChainYahoo Finance - Yahoo! Finance Canada
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Zacks Investment Research
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Amarin Highlights New ESC 2026 Data and Guideline Support Reinforcing Evidence for Icosapent Ethyl - Quiver Quantitative
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ) - Seeking Alpha
Heart treatment linked to ~30% fewer major events; benefits may persist after stopping - Stock Titan
Amarin (NASDAQ: AMRN) sees Sarissa report 25.7M+ shares - Stock Titan
Amarin Announces REDUCE-IT-Related Presentations at ESC Congress 2026 in Munich - Quiver Quantitative
Five abstracts from an 8,179-patient study are set for the 2026 heart congress - Stock Titan
Amarin (AMRN) Holds Near $14.15 as Bulls Defend Key Support ZoneMomentum Stock Picks - careplusvn.com
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – LSX:A41557 - TradingView
Earnings call transcript: Amarin Q2 2026 revenue falls, but cash flow improves - Investing.com
Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges - Yahoo Finance
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short - TradingView
Amarin Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short - Yahoo Finance
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – FWB:EH3 - TradingView
Amarin Corporation PLC expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Amarin CorpADR (AMRN) Fundamental & Financial Data - Stocktwits
AMRN: Amarin CorpADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now - Yahoo Finance
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming (NASDAQ:AMRN) - Seeking Alpha
AMRNAmarin Corp ADR Options - Finviz
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape - Barchart.com
Amarin Corporation Plc Sponsored ADR Actuals & Estimates (NASDAQ:AMRN) - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
Here's Why You Should Add ANIX Stock to Your Portfolio Now - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
Net income before discontinued operations of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Price to book ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Non-operating income (total) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Current ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Free cash flow per share of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Diluted earnings per share (diluted EPS) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – DUS:EH3 - TradingView
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma - Benzinga
Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics - Seeking Alpha
AMRNAmarin Corp ADR Short Interest - Finviz
Amarin Corp Adr Stock (AMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
6.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):